Clinical Trial

Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-2828. The study will also measure what happens to MK-2828 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive protein (hsCRP) in a person's blood.
Protocol Amendment History 5 changes
critical Trial completed 2026-05-23
notable Enrollment reduced: 64 -> 46 participants 2026-05-23
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-28
notable Primary completion moved earlier: 2026-06-29 -> 2026-05-06 2026-04-28
minor Completion moved earlier: 2026-06-29 -> 2026-05-06 2026-04-28
Trial Details
NCT Number NCT07089784
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Diabetes Mellitus, Type 2
Enrollment 46 participants
Start Date 2025-09-22
Primary Completion 2026-05-04 (estimated)
Study Completion 2026-05-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-22